Format

Send to

Choose Destination
Cell Syst. 2017 Dec 27;5(6):620-627.e3. doi: 10.1016/j.cels.2017.10.014. Epub 2017 Nov 15.

Association of Omics Features with Histopathology Patterns in Lung Adenocarcinoma.

Author information

1
Biomedical Informatics Program, Stanford University, Stanford, CA 94305-5479, USA; Department of Genetics, Stanford University, Stanford, CA 94305-5120, USA; Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA.
2
Department of Pathology, Stanford University, Stanford, CA 94305, USA.
3
Biomedical Informatics Program, Stanford University, Stanford, CA 94305-5479, USA; Department of Biomedical Data Science, Stanford University, Stanford, CA 94305, USA; Department of Radiology, Stanford University, Stanford, CA 94305-5105, USA; Department of Medicine (Biomedical Informatics Research), Stanford University, Stanford, CA 94305-5479, USA.
4
Department of Computer Science, Stanford University, Stanford, CA 94305-9025, USA.
5
Biomedical Informatics Program, Stanford University, Stanford, CA 94305-5479, USA; Department of Genetics, Stanford University, Stanford, CA 94305-5120, USA; Department of Computer Science, Stanford University, Stanford, CA 94305-9025, USA; Department of Bioengineering, Stanford University, Stanford, CA 94305-4125, USA.
6
Department of Genetics, Stanford University, Stanford, CA 94305-5120, USA. Electronic address: mpsnyder@stanford.edu.

Abstract

Adenocarcinoma accounts for more than 40% of lung malignancy, and microscopic pathology evaluation is indispensable for its diagnosis. However, how histopathology findings relate to molecular abnormalities remains largely unknown. Here, we obtained H&E-stained whole-slide histopathology images, pathology reports, RNA sequencing, and proteomics data of 538 lung adenocarcinoma patients from The Cancer Genome Atlas and used these to identify molecular pathways associated with histopathology patterns. We report cell-cycle regulation and nucleotide binding pathways underpinning tumor cell dedifferentiation, and we predicted histology grade using transcriptomics and proteomics signatures (area under curve >0.80). We built an integrative histopathology-transcriptomics model to generate better prognostic predictions for stage I patients (p = 0.0182 ± 0.0021) compared with gene expression or histopathology studies alone, and the results were replicated in an independent cohort (p = 0.0220 ± 0.0070). These results motivate the integration of histopathology and omics data to investigate molecular mechanisms of pathology findings and enhance clinical prognostic prediction.

KEYWORDS:

cancer genomics; cancer imaging; cancer proteomics; cancer transcriptomics; lung adenocarcinoma; machine learning; precision medicine; predictive medicine; quantitative pathology

PMID:
29153840
PMCID:
PMC5746468
[Available on 2018-12-27]
DOI:
10.1016/j.cels.2017.10.014

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center